# Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

> clinical trial · VERIFIED · 2026-08-19

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Recurrent Classic Hodgkin Lymphoma

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT01896999

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.